ProKidney Corp, a biotechnology company headquartered in Winston Salem, United States, has been making significant strides in the healthcare sector, particularly in the development of innovative therapies for kidney diseases. The company specializes in creating treatments that utilize patients’ own cells to repair and restore diseased kidneys. This approach aims to prevent or delay the necessity for dialysis or kidney transplants, offering a potentially transformative solution for patients suffering from kidney ailments.
As of May 13, 2026, ProKidney Corp’s stock was trading at a close price of $1.71 on the Nasdaq exchange. The company’s market capitalization stands at approximately $528.43 million. Over the past year, the stock has experienced significant volatility, with a 52-week high of $7.13 recorded on July 8, 2025, and a 52-week low of $0.54 on June 29, 2025. The price-to-earnings ratio is currently at -3.44, reflecting the company’s ongoing investment in research and development, which has yet to yield substantial earnings.
ProKidney Corp’s innovative approach involves advanced cellular reparation techniques, leveraging the body’s own cells to facilitate kidney repair. This method not only holds promise for improving patient outcomes but also represents a shift towards more personalized and regenerative medical treatments. By focusing on therapies that utilize autologous cells, ProKidney Corp aims to reduce the dependency on traditional treatments such as dialysis and organ transplants, which can be both costly and limited by donor availability.
The company’s global reach allows it to serve a diverse customer base, providing access to its cutting-edge therapies across various regions. ProKidney Corp maintains an online presence through its website, www.prokidney.com , where patients and healthcare providers can find more information about its products and services.
As ProKidney Corp continues to advance its research and expand its therapeutic offerings, it remains a notable player in the biotech industry, particularly within the niche of regenerative medicine for kidney diseases. The company’s commitment to innovation and patient care positions it as a key contributor to the evolving landscape of healthcare solutions.
